SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " quartz " 238 found 🔀 AI-powered Shuffle
Independent Kansas health systems launch shared services organization
Five Kansas health systems have launched a regional collaboration, called Astra Health, to pool resources and coordinate services while retaining their independence. | Astra Health's five founding members, who serve more than half a million patients annually, hope to improve quality and trim costs at scale while maintaining their independence.
AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD
With a detailed data drop that AstraZeneca’s R&D chief described as an internal “science success story,” the British Big Pharma has secured an FDA priority review for what it believes could become a flagship biologic in chronic obstructive pulmonary disease (COPD). In detailed results from the late-stage Oberon and Titania trials—first teased in March and detailed in full at the European Respiratory Society Congress in Barcelona this week—the drugmaker laid out the extent of its IL-33 inhibitor’s potential to reduce moderate and severe exacerbations in a wide range of COPD patients still struggling with those “lung attacks,” as AstraZeneca’s Sharon Barr, Ph.D., called them, despite using standard-care inhaled therapy. In the headline results, a 300 mg dose of tozorakimab given once every four weeks curbed those moderate and severe exacerbations in the studies’ primary population of former smokers by 29% in the Oberon study and 34% in Titania. In the overall population of both current and former smokers, these reductions were 30% and 29%, respectively, versus placebo and inhaled standard of care. The benefits also extended to clinically meaningful exacerbation reductions in all prespecified patient subgroups and specifically turned up promising signals in patients across a range of blood eosinophil counts, with Barr telling Fierce that “it’s the details that make this even more exciting than the high-level results that we’ve already shared.” In fact, during AZ’s tozorakimab poster presentation at the ERS 2026 Congress this past weekend, attendees were so enamored by the data that event organizers had to encourage people to clear the room and look at the other presentations on offer, Barr said in an interview. “I think it really speaks to the fact that there is a lot of buzz around these data because the entire respiratory community has been so desperate for new therapies for these patients,” she explained. The respiratory disease continues to represent a “staggering unmet medical need,” Barr said, highlighting the COPD exacerbations that the Oberon and Titania studies homed in on, which she added carry a greater mortality risk than a heart attack. “When a patient has a severe exacerbation, only about half of them are still alive within three and a half years,” she pointed out. As for tozorakimab specifically, Barr christened the molecule “an AstraZeneca science success story,” harkening several years back to the point at which researchers began to explore IL-33 as a driver of respiratory disease, and COPD in particular. At the same time, “there was still so much that wasn’t understood,” she admitted, highlighting the insight that IL-33 signals through both ST2 and EGFR through the RAGE pathway, a discovery Barr attributed to AstraZeneca's own scientists. Understanding the need to tackle both pathways in COPD—and aware of competitor candidates in the hopper, including one that bound ST2—the company ultimately had to make some “courageous decisions,” Barr said. These included taking a prior COPD molecule offline and going back to the drawing board to reinvent its potential IL-33 label “to make sure that we had a molecule that could block signaling through both arms of the pathway, through both the reduced form and the oxidized form, knowing that we wouldn’t be first, but striving to be best.” “When we put [tozorakimab] into the clinic, we firmly believed that we had a differentiated molecule, and we saw the other molecules blocking just ST2 or partially blocking IL-33, unable to deliver two positive pivotal studies in COPD,” Barr explained. “We kept marching forward because we believed our molecule was differentiated, and now I think we have the clinical validation that supports that.” Ultimately, AstraZeneca finds itself on much better footing these days when it comes to potential biologic rivals to tozorakimab in COPD. Sanofi and Regeneron’s Dupixent, for instance, is approved to treat COPD exacerbations in patients with high eosinophil counts, but not low ones. Meanwhile, the future has become cloudier for other next-gen IL-33 candidates from Sanofi and Regeneron, as well as Roche, which have suffered trial flops in recent years. One other potential ingredient for AstraZeneca’s success in its duo of studies was that the company was “ambitious in the trial design, willing to look at an all-comers population,” Barr said, “and willing to enroll the most severe patients.” Prior studies for would-be biologics rivals in COPD “avoided enrolling” those patients, she pointed out. She also highlighted the Big Pharma’s painstaking design of exacerbations in its trial, which “gave us a very rigorous readout,” and pointed to “the extra effort and investment” the company put in to understand the effect of mucus plugs in patients. Barr described mucus production as a “key feature in disease diversity,” noting that mucus plugs—obstructing clumps of mucus that block patients’ airways—are associated with worse outcomes in COPD. In its data announcement, AstraZeneca noted that an integrated analysis of Oberon and Titania found tozorakimab “demonstrated a reduction in patients’ mucus plug score,” with the pharma claiming its biologic is the first to deliver such results in a broad COPD population. “So being able to reduce those mucus plugs, we expect, is an important part of driving benefit for patients who are living with COPD,” Barr said. Again touching on the breadth of the study populations, Barr added that tozorakimab “worked across all eosinophil levels in both current and former smokers across all levels of lung function,” which she suggested “really simplifies decision-making for clinicians, and it allows them to offer therapy to the broadest possible patient population.” In the highest patient eosinophil count group, tozorakimab helped chart a 43% reduction in exacerbation risk, which Barr stressed were “unprecedented data.” In the mid-level group, AZ’s drug delivered a 23% reduction and, in the lowest group, a 34% reduction in eosinophils, which Barr said suggests efficacy “in all patient subgroups.” As for AZ’s recent guidance upgrade on the medicine’s sales opportunity, the lift from a $3 billion to $5 billion range to $5 billion plus was informed by multiple factors, Barr said, including the fact that “in 2024, there were multiple competitors, and there aren’t anymore.” Additionally, “we know that this is a massive unmet medical need, and this is a really incredible set of data that we think will be very convincing to the clinical community,” Barr said. Looking ahead to a potential evolution of the COPD treatment landscape, Barr noted that most patients start treatment in the community with an option like a triple therapy, and for them, having an option like AstraZeneca’s inhaler Breztri will remain a “really important part” of that journey. But of the patients uncontrolled on triple therapy, which Barr described as “about half of them today,” just a “small fraction” are currently eligible for biologic therapy, which she emphasized AstraZeneca is working to change. Understanding that COPD is not a “one-size-fits-all” disease, AstraZeneca is also looking at its antibody drug Tezspire for patients with T2-driven disease, and the company continues to think about new mechanisms for tackling COPD through both systemic and inhaled drugs, Barr said.
Parakeet Health lands major AI partnership with national dermatology group Qualderm
Parakeet Health landed a major partnership with Qualderm, one of the nation's largest dermatology organizations, as the company looks to apply agentic artificial intelligence to a growing specialty | Parakeet Health landed a major partnership with Qualderm, one of the nation's largest dermatology organizations, as the company looks to apply agentic artificial intelligence to a growing specialty care access problem.
Smart ring maker Oura files to go public, pitching investors on AI-driven preventive health
Oura, the smart ring maker and health tracking company, filed to go public on Thursday to fuel its next phase of growth as it aims to build an artificial intelligence-powered health platform. | Oura, the smart ring maker and health tracking company, filed to go public on Thursday to fuel its next phase of growth as it aims to build an artificial intelligence-powered health platform.
Healthcare Dealmakers—UHS closes Talkspace acquisition, Sanford's North Memorial deal clears and more
Healthcare mergers and acquisitions are in no short supply as providers, health tech companies, payers and other industry players look to expand their businesses and gain a competitive edge. | Sword Health nears Headspace all-cash acquisition, HCA Healthcare adds dozens of Texas urgent care centers and more healthcare merger and acquisition news from August.
Weekly Rundown: LeanTaaS acquires care transition platform Aidin; Hims expands to Australia
Stay up to date on the latest in health tech, digital health and health AI news with this weekly brief. Read below for news from the week of Aug. 31 to Sept. 4. | The latest news from Vitality, Icario, LeanTaas, Aidin, Healwell AI and Hims.
CMI boosts medical affairs capabilities with new specialty communications unit
CMI Media Group is adding to its spread of media services through a new specialty communications business that introduces a slate of new cutting-edge marketing tools. | The new business unit is centered on four core capabilities, which includes AI-enhanced scientific intelligence, omnichannel "scientific ecosystems," and more.
AI boom through 2050 hinges on power supply, politics, PwC says
PwC expects global data center capex will hit $31.6 trillion by 2050 in a base case scenario, with spe | AI may unleash a $31.6 trillion data center buildout by 2050, but PwC says the real race isn’t just for capital — it’s for power, chips and political advantages.
AI boom through 2050 hinges on power supply, politics, PwC says
PwC expects global data center capex will hit $31.6 trillion by 2050 in a base case scenario, with spe | AI may unleash a $31.6 trillion data center buildout by 2050, but PwC says the real race isn’t just for capital — it’s for power, chips and political advantages.
ChatGPT for Healthcare unveils new integrations with Epic, public health data sources
OpenAI is expanding ChatGPT's healthcare capabilities with new integrations that connect it more directly with clinical workflows and public healthcare sources. | OpenAI is expanding ChatGPT's healthcare capabilities with new integrations that connect it more directly with clinical workflows and public healthcare sources.
Sword Health to acquire Headspace in all-cash deal
Virtual physical therapy platform Sword Health is planning to acquire digital mental health company Headspace in an all-cash deal, according to a regulatory filing from the latter. | The virtual physical therapy and mental health platforms are targeting a September close, per a regulatory filing. A price tag was not disclosed, but is being reported to land between $200 million and $300 million.
Boston Scientific hit by cyberattack causing ‘disruptions’ to parts of its business
This year has seen a growing number of medtechs hit by cyberattacks, and now Boston Scientific has become the latest victim. In an SEC filing posted Aug. 26, the medtech giant said it had detected a “cybersecurity incident” the day before. The incident has affected certain parts of its information technology systems, something that “has resulted in a global disruption to the company’s operations.” The incident has hit not just its information systems but also its business applications, which “support aspects of the Company’s operations,” it said in the filing. This includes its ability to process and ship customer orders. Boston Scientific said it is working to restore the systems, but the timeline remains unknown. Related Baylor Genetics hit by cybersecurity attack targeting patient, staff information As the company investigates the incident, it remains unclear how significantly its business will be affected. “Accordingly, the Company has not yet determined whether the incident is reasonably likely to have a material impact.” The company’s shares were down 3.5% in premarket trading as the news broke. This adds another layer of pressure for the medtech, which last month revealed a new global restructuring program that starts this year and is slated to be completed by 2029. The company said at the time that it “does expect some headcount reductions to result from these restructuring activities,” but did not provide any numbers or specify areas where the cuts may be made. It added, however, that new jobs are also set to be “created in areas of growth.” It was also forced to cut its sales guidance in Q2, saying in late July that it now expects full-year 2026 organic revenue growth of 5% to 6%, down from its previous guidance of 6.5% to 8%. Boston Scientific is one of a growing number of life sciences companies, notably medtechs, that have been hit by cyberattacks this year. These include Abbott, iRhythm, Medtronic and Stryker, as well as Big Pharmas Amgen and Novo Nordisk.
Fullspan Health’s AI agent sees strong early traction with 1.1M views since June launch
Fullspan Health’s conversational artificial intelligence agent is gaining traction among users. | The conversational AI tool—dubbed Healthline AI—is sourced directly from the publisher’s medically reviewed properties.
Weekly Rundown: Expressable joins Amazon's health conditions program; Function launches data connector for AI platforms
Stay up to date on the latest in health tech, digital health and health AI news with this weekly brief. This is news from the week of Aug. 17 to 21. | Stay up to date on the latest in health tech, digital health and health AI news with this weekly brief.
Regeneron podcast turns science learnings into immersive experience
Regeneron is showing off its science in a whole new light with its “Science Illuminated” series, a unique vide | Regeneron's "Science Illuminated" podcast series transforms scientific topics into a calming, meditative-style video and audio experience.
Cityblock acquires Homeward Health to move into rural healthcare, lands $116M funding round
Cityblock Health, a company primarily focused on providing care for urban Medicaid and dual-eligible members, is acquiring Homeward Health to expand deep into rural markets, the company announced T | Combined, the two companies will serve nearly 250,000 people and are positioned to reach the120 million people receiving government-funded healthcare in the U.S., Toyin Ajayi, Cityblock Health CEO and co-founder wrote in a blog post.
Happy Health secures $75M to expand AI-powered care in the home starting with sleep apnea
Digital health company Happy Health secured a $75 million series A funding round to continue building its artificial intelligence-powered platform for continuous home-based care. | The startup’s smart ring—dubbed Happy Ring—was first cleared by the FDA in 2024.
Pennsylvania Highlights Housing Investments to Improve Health
Pennsylvania officials have committed $1 million in state funding to connect vulnerable Medicaid recipients with housing and health services. | State funding will bring housing support for Medicaid recipients with chronic health conditions.
WSDG Completes The Kempinski Grand Hotel’s Ultra-Modern Entertainment Venue At Billionaire St. Moritz
Billionaire St. Moritz, an ultra-modern event location directly connected to the historic Grand Hotel des Bains Kempinski, has opened as the ultimate dinner show and clubbing experience in St. | Acoustic and AV technology designers deliver sophisticated room-within-room construction for exclusive dinner show and clubbing experience.
Common Health Coalition secures $100M from OpenAI Foundation to boost hepatitis C cure rates
The OpenAI Foundation invested $100 million towards a new public health initiative with the Common Health Coalition aimed at helping states and local jurisdictions close discovery-to-delivery gaps, | Funding will support the deployment of AI-enabled tools to help identify patients who have fallen out of care, reduce administrative burden, strengthen care coordination and improve patient outcomes.
Abbott to pump up blood supply with $1M college sports prize amid US crisis
Abbott is again tapping into the competitive spirit of Big Ten universities to drive blood donations,
Sports fans never sleep: Ericsson says 5G is becoming central to game-day
Fans increasingly expect seamless digital experiences before, during and after sporting events, p | The World Cup may be over, but the race to improve fan experiences is not. Advanced 5G networks are increasingly shaping everything from stadium connectivity and concessions to media production and public safety.
Opinion: AI isn’t the business
AI will transform how businesses operate without replacing what makes them valuable.
AbCellera women’s health data top ‘most aggressive upside scenario,’ putting Astellas and Bayer on notice
AbCellera has reported phase 2 results “beyond even the most aggressive upside scenario” that its CEO dared to consider, boosting the biotech’s chances of challenging Astellas and Bayer for a women’s health market. The phase 2 clinical trial compared ABCL635, an antibody targeting NK3R, to placebo in patients with hot flashes caused by menopause. Investigators enrolled 92 postmenopausal women experiencing a mean of about 10 moderate or severe hot flashes per day. By Week 4, the number of moderate or severe hot flashes had fallen by a mean of 8.8 on ABCL635 and by 3.5 on placebo. That statistically significant, placebo-adjusted reduction of 5.3 hit the trial’s primary endpoint. The level of efficacy also cleared the bar set by existing drugs. While cross-trial comparisons can be misleading, AbCellera CEO Carl Hansen, Ph.D., had seen enough to start hyping the program. “We now view ABCL635 as a potential best-in-class non-hormonal therapy with strong differentiation against approved NK3R competitors across all important dimensions, including efficacy, safety, dosing and convenience,” Hansen said on a Monday morning conference call with investors to discuss the data. “We believe ABCL635 is now a highly de-risked program.” Last week, Hansen used AbCellera’s earnings call to set expectations for readout, with the CEO defining success as a clean safety profile and efficacy comparable to the two approved small molecules. The data vaulted over that bar. Astellas linked (PDF) one of the small molecules, Veozah, to placebo-adjusted reductions in hot flash frequency of 2.1 and 2.6 at Week 4 of its two phase 3 trials. Bayer reported (PDF) placebo-adjusted reductions of 3.04 and 3.29 at Week 4 of pivotal studies for its small molecule, Lynkuet. At 5.3, the placebo-adjusted reduction in AbCellera’s trial comfortably cleared the standard set by the incumbents. Veozah and Lynkuet came to market based on evidence of their ability to reduce the frequency and severity of hot flashes. AbCellera’s phase 2 study covered both endpoints, with the Canadian biotech reporting a mean reduction in severity of 1.4 points at Week 4 on ABCL635, compared to 0.3 points for placebo. Again, the placebo-adjusted result compares favorably to data on Veozah and Lynkuet. Analysts shared Hansen’s enthusiasm for the data. The phase 2 results “firmly validate ABCL635 as a potentially best-in-class treatment,” BMO Capital Markets analysts said in a note to investors Monday. ABCL635’s apparent efficacy edge “is likely attributable to the higher dosing/target engagement the asset is able to reach vs. the oral agents due to its wider therapeutic index,” the analysts added. The analysts, who model $2.3 billion in unadjusted peak sales for ABCL635, flagged the safety profile as another positive of the phase 2 readout. While Veozah carries a boxed warning for liver damage, nobody on ABCL635 in the phase 2 trial had elevated liver enzymes or bilirubin values. If replicated in phase 3, the lack of a liver signal could allow approval without the monitoring requirements imposed on Veozah. Investors appeared equally enthused, sending AbCellera's stock up 32% to $9.21 in premarket trading Monday from a Friday closing price of $6.93. Next, AbCellera will collect the Week 12 data and talk to its advisors about further development. The results open up “a wide variety of possibilities of how we might take this forward into phase 3 studies to truly maximize the value of the asset and make sure that ABCL635 is able to demonstrate its differentiation potential,” Sarah Noonberg, M.D., Ph.D., AbCellera’s chief medical officer, told investors.
AHF Launches Health and Housing Newsletter
There is growing recognition that housing is more than a roof over someone’s head—it’s a critical driver of health and well-being. | The newsletter comes as the two sectors are working together for better resident, business, and community outcomes.
Seiko's $750 Speedtimer Chronograph Gets a New "Edo Purple" Dial
The affordable Prospex Speedtimer, equipped with a solar quartz movement, receives a "purple panda" dial revamp.
Building Business Success On A Solid Foundation
Grady Wold, owner of Trend Stone Surfaces, understands the importance of building a business on a solid foundation. When he needed a financial partner to help expand his granite and quartz countertop business, he turned to Security Financial Bank (SFB), where he works with Scott Erickson, Bloomer
Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’
Sanofi halted a phase 2 trial testing a monoclonal antibody, SAR445399, in non-cystic fibrosis bronchiectasis, Fierce Biotech has learned. The trial, which began only back in April, was a randomized, double-blind, placebo-controlled study to measure the reduction in mucus plug score following treatment with SAR445399 compared with placebo in adults aged 18 to 80 years with NCFB, a chronic lung disease. The trial was officially reported as halted on July 29, the day before Sanofi’s second-quarter earnings call. The decision to pause the trial was made “as part of a company-wide portfolio review for strategic business reasons,” and not due to safety concerns, a Sanofi spokesperson told Fierce. The move to pause the NCFB trial comes during a trying time for Sanofi following a year filled with a series of trial fails. In February, the French pharma ousted CEO Paul Hudson and appointed Merck KGaA leader Belén Garijo, M.D., Ph.D., to steer the ship. Since then, Garijo has been doing a deep dive on correcting the company’s strewn R&D and clinical strategies. On July 24, Sanofi scrapped amlitelimab for atopic dermatitis, despite its lore as being a potential $5 billion blockbuster. During its second-quarter report, the company abandoned two more assets, balinatunfib and itepekimab, following failed trial results in psoriasis and chronic obstructive pulmonary disease, respectively. SAR445399, only first revealed by Sanofi in 2023, is an anti-interleukin-1 receptor 3 monoclonal antibody developed to block the interleukin 1, 33, and 36 cytokine pathways. These pathways can be important in chronic immune-related dermatologic diseases, such as atopic dermatitis and hidradenitis suppurativa, as well as respiratory conditions, such as NCFB. Related Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues NCFB affects roughly half a million people in the U.S., with a global incidence of greater than one million cases. In August 2025, Insmed received FDA approval for Brinsupri, a DPP1 inhibitor targeting neutrophil activation, for treatment of NCFB in adults and kids ages 12 and older. The British biotech Infex Therapeutics showed promising NCFB phase 2a data using their monoclonal antibody, INFEX702, which acts by disabling Pseudomonas aeruginosa, a bacteria known to be a major pathogen of NCFB. Sanofi is currently running a separate phase 2 study testing SAR445399 as a potential treatment for the inflammatory skin condition hidradenitis suppurativa.
Amgen says patient health data, IP stolen in cybersecurity breach
Hackers recently accessed Amgen’s cloud environment, stealing sensitive patient health information and proprietary company data, the company disclosed in a securities filing on Friday. | Hackers recently accessed Amgen’s cloud environment, stealing sensitive patient health information and proprietary company data, the company disclosed in a securities filing on Friday.
Tesla weighs sale of China business ahead of SpaceX merger
The Wall Street Journal reports some Tesla executives have been told to prepare for a separation of the company's China operations
Wellstar Health System lays off 761 corporate, administrative staff
Wellstar Health System laid off 761 workers yesterday “following a comprehensive review of our organization,” the Georgia nonprofit confirmed to Fierce Healthcare. | The cuts translate to about 2% of the nonprofit system's headcount, and do not include frontline care roles.
AI doctor startup Doctronic acquires Summer Health to move into pediatric care
AI doctor startup Doctronic aims to broaden its reach beyond adult primary care by acquiring text-based pediatric care platform Summer Health. | AI doctor startup Doctronic aims to broaden its reach beyond adult primary care by acquiring text-based pediatric care platform Summer Health.
Included Health inks agreement to acquire Firefly Health to scale alternative health plans for employers
Virtual care and health navigation company Included Health inked a deal to acquire Firefly Health to scale health plan alternatives for employers. | Virtual care and health navigation company Included Health inked a deal to acquire Firefly Health to scale health plan alternatives for employers.
OpenAI makes Health in ChatGPT widely available, moving deeper into consumer health
OpenAI on Thursday made its Health in ChatGPT feature broadly available, enabling U.S. users to connect its artificial intelligence chatbot with medical records and wellness apps. | OpenAI on Thursday made its Health in ChatGPT feature broadly available, enabling U.S. users to connect its artificial intelligence chatbot with medical records and wellness apps.
Teladoc Health unveils new virtual care model for employers, health plans that ties payment to results
Teladoc Health unveiled a new virtual care model for employers and health plans designed to offer a more coordinated, personalized approach for members, while tying payment to clinical and financia | Teladoc Health unveiled a new virtual care model for employers and health plans designed to offer a more coordinated, personalized approach for members, while tying payment to clinical and financial outcomes.
Lakelin Lemmings Signs With The Kinkead Entertainment Agency
QHMG/Quartz Hill Records artist Lakelin Lemmings has inked with The Kinkead Entertainment [...]
Erlanger Health System signs letter of intent to join Prisma Health
Erlanger Health System plans to join Prisma Health, creating a 27-hospital system in exchange for a $2 billion strategic capital commitment toward care in the Chattanooga, Tennessee area. | The tentative deal includes a $2 billion strategic capital commitment from Prisma, and would yield a 27-hospital, $9 billion operating revenue nonprofit in the southeast.
Cardinal Health to buy Strive Medical, AdaptHealth's diabetes health business for $360M
Cardinal Health is pursuing two tuck-in acquisitions to expand its home care business. | The pharmaceuticals and specialty products distributor plans to buy AdaptHealth's diabetes health business unit and medical supply provider Strive Medical in separate deals worth $360 million.
AdventHealth, Intermountain Health plan to form Denver-area joint venture
Nonprofit health systems AdventHealth and Intermountain Health announced plans Tuesday to bring Denver-area hospitals and ambulatory sites under a new, to-be-formed joint venture. | The entity would comprise five AdventHealth hospitals, three Intermountain hospitals and their affiliated sites. It would be managed by AdventHealth, which is also expected to be the joint venture's majority owner.
AMC Entertainment Q2 2026 earnings: record revenue, surprise profit
The theater chain beat Wall Street estimates on both revenue and earnings as attendance climbed in the U.S. and Europe
Germany pushes through healthcare reform package despite pharma's drug discount resistance
Even as the effort has met with fierce pushback from drugmakers, trade groups and opposition parties in the country’s own government, German lawmakers late Friday voted to pass health insurance ref | Even as the effort has met with fierce pushback, German lawmakers late Friday voted to pass health insurance reforms aiming to cut healthcare costs, in part by hiking up mandatory rebates that pharmas must pay on branded medicines.
Apollo inks €3B equity deal for stake in Bayer's contraceptives business
Amid restructuring efforts, Bayer has addressed its need for a capital infusion in pharma under a deal
Illumina names new commercial, legal chiefs as sequencing business shows signs of stability
Illumina has filled two key C-sui | Illumina has filled two key C-suite posts, naming Mike Sullivan as chief commercial officer and Julie Coletti as chief legal officer as the DNA sequencing giant works to keep its turnaround on track after years of regulatory, geopolitical and investor turbulence.
Titan OS adds 30 Radial Entertainment FAST channels in Europe
Titan OS is adding and expanding reach of 30 free ad-supported streaming TV channels from Radial Entertainment’s FilmRise to its smart TV OS-powered device footprint across Europe. | Expansion of FilmRise channels internationally is currently a top priority for Radial, the company said.
Haleon teams up with Microsoft in 5-year AI pact to upgrade consumer health operations
Consumer health giant Haleon has tapped Microsoft to incorporate AI across its operations, joining a growing wave of healthcare and life sciences heavyweights turning to Big Tech to execute enterpr | Consumer health giant Haleon has tapped Microsoft to incorporate AI across its operations, joining a growing wave of healthcare and life sciences heavyweights turning to Big Tech to execute enterprise-wide digital overhauls.
ACCESS Model: behavioral health edition
A new value-based care program for chronic condition management begins July 5. | A new payment model is designed to pay digital health companies based on outcomes in chronic condition management. But where does behavioral health fit? This episode explores that question with SonderMind and Headspace, two companies participating in the model's behavioral health track.
Trafalgar Entertainment Announces Acquisition Of The London Theatre Company
Trafalgar Entertainment is delighted to announce its acquisition of the London Theatre Company (LTC). | The deal includes The Bridge Theatre and a King’s Cross venue which hosts immersive entertainment business, Lightroom.
PPDS Brings 'Limitless' TV Entertainment To Historic 5 Star Bellevue Syrene Hotel With Philips MediaSuite
PPDS, the exclusive global provider of Philips Professional Displays, has announced that its Philips MediaSuite TV range has been chosen to deliver seamless access to a virtually limitless world of | Delivering modern luxuries to the 18th century hotel in Sorrento, Philips MediaSuite TVs with cast built in are now bringing seamless access to millions of movies, TV shows, games, and streaming apps to guests at one of Italy's most prestigious and exquisite hospitality destinations.
Assort Health scores $120M series C to scale voice AI agent platform for healthcare
Assort Health picked up $120 million in series C funding, hitting unicorn status, to fuel the company's work building out a voice AI agent platform for healthcare. | Assort Health has a large proprietary specialty dataset built on 190 million patient interactions, 62,000 care protocols and 1.6 million decision pathways.
DOJ announces $6.5B healthcare fraud takedown with record Medicaid enforcement
The Department of Justice unveiled charges against 455 people, including 90 doctors and other licensed medical professionals, for their alleged participation in healthcare schemes that involved mor | Law enforcement unveiled charges against 455 defendants for their alleged participation in healthcare schemes, among which fraudulent amniotic wound allografts and undelivered Medicaid services were spotlighted.
Hallmark Health Care Solutions launches AI solution to tackle workforce ‘black box’
Hallmark Health Care Solutions built an artificial intelligence-enabled platform to give health systems more visibility and control of workforce cost, capacity and incentives. | Health systems partnering with Hallmark have seen significant measurable results, including reducing contingent labor expenses by 15% to 25% and lowering overtime costs by an average of 25%.
A look at Elevance Health's push to streamline clinical reviews
Elevance Health is making strides toward a simpler and more streamlined clinical review process through its Health OS platform. | Elevance Health is making strides toward a simpler and more streamlined clinical review process through its Health OS platform.
Federal health agencies unveil plan to speed up phase 1 clinical trials by 6 to 12 months
As the biotech world flocks to San Diego today for the BIO International Convention, the Department of Health and Human Services has provided plenty of conversation fodder with the announcement of | As the biotech world flocks to San Diego today for the BIO International Convention, the Department of Health and Human Services has provided plenty of conversation fodder with the announcement of a series of efforts to regain ground on China’s surging early-stage clinical development capabilities.
Prosper AI lands $30M backed by Andreessen Horowitz to build AI workforce for healthcare operations
Nine months after announcing its seed funding round, Prosper AI banked $30 million to scale its agentic AI platform to power administrative tasks from patient scheduling to insurance verification a | Prosper AI banked $30 million to scale its agentic AI platform to power administrative tasks from patient scheduling to insurance verification and patient billing.
GFiber gets into bulk-billing, managed Wi-Fi business for MDUs
The new offering brings fiber to every unit of a multi-dwelling property
GFiber gets into bulk-billing, managed Wi-Fi business for MDUs
The new offering brings fiber to every unit of a multi-dwelling property
The top 10 nonprofit health systems by 2025 operating revenue
The 2025 fiscal year saw across-the-board performance improvements for the country’s 10 largest nonprofit health systems, if not necessarily an expansion of their business. | Operating performances may have improved across the board, but not all of the country's largest nonprofit health systems grew their businesses.
Quartz countertops are driving a public health crisis in the US – 2 occupational health experts explain the surge of lung transplants and lawsuits
Workers are facing a preventable and incurable lung disease from a material being used to renovate kitchens in millions of American homes.
Radial Entertainment’s new Blue Ant Media distribution deal
Radial Entertainment, operator of the largest independent catalog of film and television in the industry, today announced a new distri | Radial bought streaming rights to three new true crime series: “History Unsolved: The Investigation Files,” “Last Night Out” and “Fatal First Dates.”
ACT Entertainment & NETGEAR Partner To Power The Future Of Networked Live Production
LAS VEGAS ― ACT Entertainment and NETGEAR have announce | The partnership establishes interoperability between NETGEAR Switches and key technologies from ACT’s tvONE, Green Hippo and lighting control brands.
Health services deal value holds steady in 2026 with higher bar for investment: PwC
The number of health services deals dipped in the first half of 2026 but deal value "remained resilient" as strategic acquirers and dealmakers "reprice risk," according to a midyear outlook report | The number of health services deals dipped in the first half of 2026 but deal value "remained resilient" as strategic acquirers and dealmakers "reprice risk," according to a midyear outlook report from PwC.
Adaptive plots splitting Pfizer-partnered drug discovery unit from diagnostics business
Adaptive Biotechnologies is planning to separate its drug discovery and diagnostics businesses,
CMS creates new health tech office to lead interoperability efforts, digital products
The Centers for Medicare and Medicaid Services (CMS) aims to play a bigger role in health tech modernization efforts, including leading interoperability initiatives. | The Centers for Medicare and Medicaid Services (CMS) aims to play a bigger role in health tech modernization efforts, including leading interoperability initiatives.
InStride Health lands $30M series C to expand pediatric mental health services
InStride Health, a provider of specialty mental healthcare to children, teens and young adults, landed $30 million in series C funding to fuel its growth as it expands to new markets and broadens i | InStride Health, a provider of specialty mental healthcare to children, teens and young adults, landed $30 million in series C funding to fuel its growth as it expands to new markets and broadens its network of payer partners.
4Wall Entertainment Welcomes Trey Kerr As VP Of Music Production
Trey Kerr, longtime broadcast and video director for Phish and recent CEO of Gateway Production Services and Studios, has joined 4Wall as VP of | Trey Kerr, longtime broadcast and video director for Phish and recent CEO of Gateway Production Services and Studios, has joined 4Wall as VP of Music Production.
Google exits CBRS SAS administration business
The company is not accepting new customers and is giving existing customers until June 10, 2027, to tr | Google is shutting down its Spectrum Access System (SAS) business and telling Citizens Broadband Radio Services (CBRS) customers to migrate to a new SAS provider by June 10, 2027.
K-Pop Powerhouse SM Entertainment Elevates Global Hitmaking With Solid State Logic ORACLE
Seoul, South Korea, June 9, 2026 — SM Entertainment, the multinational record label, talent agency, production company and music publisher that pioneered the introduction of Korean music artists to | From shaping the sound of modern K-pop to scaling world-class production, SM adopts ORACLE to supercharge workflow, streamline sessions, and deliver signature SSL analogue excellence.
Report: U.S. Business Travel Now Accounts for More Than 2% of Economy
Business travel within and to the United States continues to be a major engine powering the nation’s economy and growth, generating $623.8 billion in total gros | Findings reveal business travel supports 6.7 million U.S. jobs and accounts for 2.1% of GDP, underscoring its role as a critical driver of economic growth nationwide.
Resmed snaps up Noctrix Health in $340M sleep tech deal
Resmed has closed its $340 million acquisition of Noctrix Health, picking up a wearable neuromodulation device that pushes the sleep tech giant beyond its core sleep apnea and respiratory care busi | Resmed has closed its $340 million acquisition of Noctrix Health, picking up a wearable neuromodulation device that pushes the sleep tech giant beyond its core sleep apnea and respiratory care businesses.
Elation Health acquires Aster as it ramps up agentic AI for primary care
Health tech company Elation Health acquired startup Aster to propel the company's development of an agentic AI operating system for primary care. | Health tech company Elation Health acquired startup Aster to propel the company's development of an agentic AI operating system for primary care.
GBTA: U.S. business travel spending hits record $538.5B in 2024
Business travel spending in the U.S. | The report—based on 2024 data—found that business travel accounted for 2.1 percent of total U.S. GDP and generated $148.6 billion in federal, state and local tax revenue.
Stepful banks $55M to scale AI-powered medical training to boost the workforce pipeline
Healthcare staffing shortages are a near-universal problem for healthcare providers. | The company currently works with more than 35 major healthcare systems and has graduated over 32,000 practice-ready healthcare workers since its founding.
Tibet quartz discovery boosts China’s self-sufficiency push for hi-tech materials
WellSpan Health strikes strategic partnership with Philips to deploy, co-develop new healthcare tech
Community health system WellSpan Health inked a seven-year strategic alliance with Philips to drive advanced imaging technology across its network and co-develop new AI and tech tools. | WellSpan Health inked a seven-year strategic alliance with Philips to drive advanced imaging technology across its network and co-develop new healthcare technology.
grandMA3 And ACT Entertainment’s DisplayStations Support CMU School Of Drama’s Production Of “Company”
Pittsburgh-based Carnegie Mellon University’s School of Drama utilized several grandMA3 consoles for lighting control and DisplayStations for designer stations on its latest production, Stephen Son | Pittsburgh-based Carnegie Mellon University’s School of Drama utilized several grandMA3 consoles for lighting control and DisplayStations for “Company.”
Enzo Health launches agentic EHR for home health agencies
Health tech startup Enzo Health rolled out an AI-native electronic health record (EHR) system designed for home healthcare agencies, touting it as an industry first. | With the platform, organizations can seamlessly run all operations, including intake, scheduling, visits, quality compliance, billing and visibility for patients, the company said.
Caesars Entertainment to be acquired for $17.6B
Caesars Entertainment has entered into a definitive agreement to be acquired by Fertitta Entertainment in an all-cash transaction valued at approximately $17.6 billion, including the assumption of | Fertitta Entertainment will acquire Caesars Entertainment in an all-cash transaction.
Teladoc Health inks partnership with Walmart to expand virtual care services
Teladoc Health is expanding its retail partnerships with a new tie-up with Walmart to offer its virtual care services through the company's Better Care Services platform. | Teladoc Health is expanding its retail partnerships with a new tie-up with Walmart to offer its virtual care services through the company's Better Care Services platform.
Quorum Health transitioning to nonprofit for financial pickup
Quorum Health announced Thursday it will be transition into a nonprofit system in order to better navigate financial challenges pressuring healthcare delivery. | The 11-hospital system made it clear that its transaction, set to close in the fall, is in pursuit of new streams of financial support.
ACT Entertainment Showcases New MA Lighting grandMA3 onPC DMX-key At InfoComm 2026
LAS VEGAS ― The new MA Lighting grandMA3 onPC DMX-key, a powe | The new MA Lighting grandMA3 onPC DMX-key will be presented by ACT Entertainment at InfoComm 2026 (Booth N6813).
Quartz
Quartz is a guide to the new global economy for people who are excited by change. We cover business, finance, economics, technology, lifestyle, and leadership.
Lauxera Capital Partners raises a hefty €520M for health, medtech companies
Lauxera Capital Partners has nearly doubled the size of its first funding drive with a €520 million ($605 million) raise for health and medical technology companies. | Lauxera Capital Partners has nearly doubled the size of its first funding drive with a €520 million ($605 million) raise for health and medical technology companies.
Ardent Health taps Fujifilm’s AI-enabled patient imaging platform
Fujifilm Healthcare Americas Corp. has signed a deal with Ardent Health to bring its enterprise imaging software to hospitals and clinics in six states. | Fujifilm Healthcare Americas Corp. has signed a deal with Ardent Health to bring its enterprise imaging software to hospitals and clinics in six states.
Health execs persevere in new policy landscape
Despite a prolonged period of policy uncertainty in the U.S.—and the ripple effects across the global life sciences and healthcare industries—executives at health companies are still seeing opportu | Despite a prolonged period of policy uncertainty in the U.S.—and the ripple effects across the global life sciences and healthcare industries—executives at health companies are still seeing opportunities amid the tumult.
Salesforce, Echo Health Ventures back Optura's $17.5M series A to track AI performance
Healthcare organizations are rapidly adopting artificial intelligence technologies but without a clear blueprint for how to measure the business value of these investments. | Optura claims that more than $2 billion in AI initiatives currently run on its platform, with $120 million in tracked value at a 700% return on AI investment on in-flight initiatives.
Haleon tackles sports injuries with latest soccer play
Haleon has completed a hat-trick of recent soccer initiatives, inki | Haleon has completed a hat-trick of recent soccer initiatives, inking a pain management partnership with the organization responsible for protecting the health and safety of players in Europe.
OVID Health hires Edelman alum Davide Scalenghe to boost its international footprint
Davide Scalenghe has joined OVID Health as its head of global strategy and partnerships. | OVID Health has hired former Edelman global public health lead Davide Scalenghe to expand the agency’s international strategy and partnerships work.
Eli Lilly shoots for health in new Caitlin Clark ad campaign
Flashy three pointers; top athletes playing under the lights; cameras focusing in on our celebrity making a game-winning shot—all elements you’d typically associate with a Big Pharma ad featuring a | Flashy three pointers; top athletes playing under the lights; cameras focusing in on our celebrity making a game-winning shot—all elements you’d typically associate with a Big Pharma ad featuring a major athletic celebrity. Not for Eli Lilly though.
ACT Entertainment Features Visual Productions NetPanel User Interfaces At InfoComm 2026
LAS VEGAS ― The new Visual Productions NetPanel Series will be showcased at InfoComm 2026 (
Nokia sells FWA business to Inseego
The transaction is expected to double Inseego’s revenue and give it a global reach | Inseego CEO Juho Sarvikas is making good on his promise to seize new business opportunities for fixed wireless access (FWA): acquiring Nokia’s FWA CPE business.
Nokia sells FWA business to Inseego
The transaction is expected to double Inseego’s revenue and give it a global reach | Inseego CEO Juho Sarvikas is making good on his promise to seize new business opportunities for fixed wireless access (FWA): acquiring Nokia’s FWA CPE business.
Sphere Entertainment Names Rob McHenry Head Of Ventures, Sphere
Burbank, CA – Sphere Entertainment Co. | Mr. McHenry is the former Deputy Director and Acting Director of the Defense Advanced Research Projects Agency (DARPA).
T-Mobile launches SuperBroadband for business customers
The service combines T-Mobile's 5G network with SpaceX's Starlink satellites and claims to reach every ZIP code in the U.S.
MSC Cruises Expands Family Entertainment on MSC World Asia
From innovative game shows and immersive technology experiences to thrilling outdoor adventures for all generations, MSC Cruises is unveiling a new world of family entertainment ab | Standout venues include MSC Luna Park Arena with interactive game shows, The Clubhouse for active family fun, and The Harbour, an open-air theme park.
Thermo Fisher Scientific sells microbiology business for $1B to European private equity firm
Thermo Fisher Scientific is shedding its microbiology business to private equity firm Astorg nearly a year after initial rumors of a sale surfaced. | Thermo Fisher Scientific is shedding its microbiology business to private equity firm Astorg nearly a year after rumors of a potential sale first surfaced.
Daiichi pushes back annual report, citing reviews amid ‘rapidly changing business conditions’
Daiichi Sankyo has postponed its annual report by two weeks to allow for additional time to finalize the financial figures. | Daiichi Sankyo has postponed its annual report by two weeks, citing additional time needed to review “the supply plans for its oncology products portfolio and development pipeline.”
Elevance Health raises 2026 outlook as it posts $1.8B in Q1 profit
Elevance Health is raising its guidance for 2026 even as its Q1 profits declined year-over-year. | Elevance Health is raising its guidance for 2026 even as its Q1 profits declined year-over-year.
Omnicom brews Olixir from FCB Health, rebranding storied agency after Interpublic takeover
Omnicom Health has stamped its mark on the recently acquired FCB Health New York,
Abbott survey finds ‘information overload, confusion and cost’ affecting health choices in US
Too much information, uncertainty and financial worries are hitting Americans when it comes to making important choices for their health. | Too much information, uncertainty and financial worries are hitting Americans when it comes to making important choices for their health.
Novartis pumps up community health footprint to tackle heart disease and cancer
Novartis is